Caption Health receives regulatory approvals for the Caption AI™ technology platform in Canada and Australia

Recent approvals position Caption for broad impact on global health by improving access to innovative heart health technology

BRISBANE, CA, November 10, 2022 /PRNewswire/ — Inscription Healththe leader in the use of AI and services to improve access to cardiac ultrasound diagnostics, announced new regulatory approvals to market its Caption AI™ technology platform from Health Canada’s Medical Devices Directorate and of Australia Administration of therapeutic goods. Echocardiography is preferred initial imaging modality to evaluate patients with suspected heart failure, and Caption Health expects its global growth to enable widespread access to earlier and more accurate cardiac care, particularly within underserved populations and regions, as it has begun to do in the U.S.

These are the second and third international regulatory approvals this year for Caption AI, following the announcement of the European CE mark this summer. The platform, which received its first regulatory approval from the US Food and Drug Administration in 2020, enables any healthcare professional to perform cardiac ultrasound without prior sonography experience. In the past year, the company launched its Caption Care service – bringing innovative diagnostic imaging to clinics and homes at scale for the first time – and partnered with a number of companies to expand the impact of early disease detection and optimize the management of heart failure.

“Our strategic global expansion is about more than market access, it’s about patient access,” he said Steve Cashman, CEO of Caption Health. “For the first time, we have the opportunity to improve and even save millions of lives by using cutting-edge technology to identify heart health problems before they become intractable.” We are excited to take these next steps.”

Wider access to cardiac ultrasound is critical to global health, experts say 64 million people worldwide – and growing – you have heart failure. Because symptoms usually don’t appear until late in the disease, heart failure is usually diagnosed in a hospital after advanced disease leads to an emergency. Despite the benefits of early detection, patients may lose out in some Canadian provinces more than a year pending echocardiogram.

And although early intervention can halt or slow progression and save lives, geography often dictates outcomes: for example, heart failure is endemic and the resulting mortality is high among Indigenous Australians living in rural areas.

“These new approvals are further confirmation of our strong clinical and regulatory history and a leading indicator of our growth potential as we work to reduce the global burden of heart disease,” they said Tahir Rizvi, head of regulatory affairs and quality assurance at Caption Health. “We will continue to execute on this strategy and expect to make an immediate impact in new markets such as Canada next year.”

Caption Health is a sponsor of HLTH 2022. Learn more and book a live demo at booth 541:

About Caption Health

Caption Health has developed an AI platform that enables access to cardiac ultrasound for early detection of disease – when it has the greatest potential for impact. The company’s Caption Care services offer healthcare providers, payers and value-based care organizations a convenient and cost-effective echo for their members using the Caption AI technology platform. In 2021, Caption Health was recognized as one of TIME’s 100 Best Inventions and a winner of Fast Company’s Next Big Things in Tech for Health. Caption Health’s platform is used in leading hospitals, clinics and physician organizations and has been cited in several peer-reviewed journals including JAMA Cardiology and Journal of the American Society of Echocardiography. For more information visit

Media contacts:

Inscription Health
[email protected]

SOURCE Caption Health

Leave a Comment

Your email address will not be published. Required fields are marked *